Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Translation of Data from Animal Models of Cancer to Immunotherapy of Breast Cancer and Chronic Lymphocytic Leukemia

Advancing cancer immunotherapy: from innovative preclinical models to clinical insights

Humanized Mouse Models for Immuno-oncology Drug Discovery

Mathematical modeling of cancer immunotherapy for personalized clinical translation

Canine cancer immunotherapy studies: linking mouse and human

Humanized Rodent Models for Cancer Research

Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes

Mouse Tumor Models for Advanced Cancer Immunotherapy

Humanized Germ-Free Mice for Investigating the Intervention Effect of Commensal Microbiome on Cancer Immunotherapy

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice

Mouse models in oncoimmunology

Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic

Transgenic Mouse Models in Cancer Research

Adoptive cell transfer: new perspective treatment in veterinary oncology

Immune characterization of pre-clinical murine models of neuroblastoma

How Animal Models of Leukaemias Have Already Benefited Patients

Improved characterization and translation of NK cells for canine immunotherapy

Translational History and Hope of Immunotherapy of Canine Tumors

Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia.

Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy

Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology